BrightGene Bio-Medical Technology
Pharmaceutical company integrating active-ingredient, formulation and innovative-drug development.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Type 2 Diabetes Mellitus (T2DM)
A Study of BGM0504 in Participants with Type 2 DiabetesPhase 3 · Recruiting · Type 2 Diabetes Mellitus (T2DM)
A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaPhase 3 · Recruiting · Type 2 Diabetes (T2DM)
A Study of BGM0504 in Early T2DM With ObesityPhase 3 · Recruiting · Type 2 Diabetes (T2DM)
A Study of BGM0504 in Participants With ObesityPhase 2 · Recruiting · Obesity
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsPhase 1 · Recruiting · Non-diabetic Overweight or Obese
Selected patent records
remdesivir · Expires 2029-04-22
US RE46762remdesivir · Expires 2029-04-22
US 8008264remdesivir · Expires 2029-09-06
US 8318682*PEDremdesivir · Expires 2029-10-22
US RE46762*PEDremdesivir · Expires 2029-10-22
US 8008264*PEDremdesivir · Expires 2030-03-06
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/brightgene-bio-medical-technology/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.